U.S. Leisure Stock News

CME Group Inc. reported past first-quarter 2026 results with revenue of US$1,880.1 million and net income of US$1,154.3 million, alongside higher basic and diluted earnings per share from continuing operations compared with a year earlier. During the same period, CME Group completed a US$800.12 million share repurchase program that reduced its share count by 0.77%, incrementally lifting earnings per share. We’ll now examine how CME Group’s strong first-quarter earnings growth and completed...

If you are wondering whether MYR Group at around US$468.54 is offering value after such a strong run, or if you are late to the story, this article focuses squarely on what the numbers say about the stock's price. The share price has moved sharply, with returns of 41.6% over the past week, 64.0% over the past month, 106.7% year to date and 206.4% over the past year, which has naturally sharpened interest in what is now priced in. Recent coverage has centered on MYR Group's role as a...

Morningstar (NasdaqGS:MORN) has launched the Europe Modern Market 50 Index, a hybrid benchmark tracking major public and high growth private companies in Europe. The index combines large listed equities with influential late stage, venture backed private firms to reflect their growing role in European equity markets. The product draws on Morningstar’s private markets data capabilities through its PitchBook subsidiary. For you as an investor, the launch highlights how Morningstar is leaning...

ON Semiconductor (ON) has just posted its latest quarterly scorecard, with Q4 2025 revenue at US$1.5b and basic EPS of US$0.45. This sets the stage against a year earlier period that saw Q4 2024 revenue of US$1.7b and basic EPS of US$0.89. Over the past few quarters, the company has reported revenue of US$1.4b and basic EPS of US$1.15 in Q1 2025, and revenue of US$1.5b and basic EPS of US$0.63 in Q3 2025. This progression gives investors a clearer view of how the top line and EPS are tracking...

IDEAYA Biosciences Q1 2026 Earnings: Revenue Context and Persistent Losses IDEAYA Biosciences (IDYA) has just reported its Q1 2026 results, and investors are looking at them through the lens of a business that recently generated Q4 2025 revenue of US$10.9 million alongside a basic EPS loss of US$0.94 and a net loss of US$83.3 million. The company has seen quarterly revenue range from US$0 to US$207.8 million over the past year, with basic EPS swinging between a profit of US$1.35 and losses of...

Ralliant’s recent trading performance Ralliant (RAL) has drawn investor attention after a mixed stretch in the stock, with a roughly 10.6% gain over the past month contrasting with a 17.5% decline over the past 3 months. See our latest analysis for Ralliant. Looking beyond the recent rebound, Ralliant’s share price return over the past 7 days of 6.0% and 30 days of 10.6% contrasts with a 90 day share price return decline of 17.5%. This suggests momentum is recovering after earlier...

Q1 earnings as the key catalyst Central Bancompany (CBC) has been in focus after first quarter results showed net interest income of US$208.62 million and net income of US$111.09 million, compared with US$189.27 million and US$94.8 million a year earlier. See our latest analysis for Central Bancompany. The stock has picked up momentum in recent months, with a 13.70% 1 month share price return and 14.84% year to date, while the 5 year total shareholder return of 163.92% highlights a much...

GPGI, the operating platform of Resolute Holdings Management (NYSE:RHLD), has acquired Husky. The deal adds another fee generating business to RHLD's platform and supports its earnings base. The acquisition is intended to support both organic expansion and further acquisitions for RHLD. Resolute Holdings Management, through its GPGI platform, focuses on building a recurring management fee base that can scale over time. The addition of Husky fits this model by broadening the pool of fee...

Ardent Health, Inc. has released its first quarter 2026 results, showing sales of US$1.60 billion versus US$1.50 billion a year earlier, with net income at US$39.85 million compared to US$41.38 million, while earnings per share from continuing operations dipped slightly year on year. Alongside this mix of higher revenue and modestly lower earnings, Ardent reported a 26.3% increase in Adjusted EBITDA, reaffirmed its full-year 2026 guidance, and highlighted progress on its IMPACT cost-saving...

Wondering if Interparfums at around US$91.70 is offering good value right now, or if the stock’s recent swings are masking what it is really worth. The share price closed at US$91.70, with returns of around 1.2% over the last month and 7.3% year to date, while the 1 year return of a 21.1% decline gives a very different picture to the 45.9% gain over 5 years. Recent news flow around Interparfums has focused on its position within the Personal Products space and how investors are reassessing...

Texas grant puts Applied Optoelectronics (AAOI) Sugar Land expansion in focus Applied Optoelectronics (AAOI) has secured a US$20,852,518 Texas Semiconductor Innovation Fund grant tied to its Sugar Land manufacturing expansion, drawing investor attention to the stock as AI focused data center transceiver capacity scales. See our latest analysis for Applied Optoelectronics. The Texas grant lands after a sharp re-rating of Applied Optoelectronics, with a 30 day share price return of 73.78% and a...

Vitesse Energy (VTS) has just reported its Q1 2026 production metrics, with realized hedged prices of US$1.54 for gas and US$61.85 for oil, alongside unhedged prices of US$2.29 for gas and US$66.76 for oil. These figures help set the tone for how the quarter’s revenue and earnings will filter through. Over the past year, the company’s total revenue has ranged from US$50.98 million in Q4 2024 to US$75.58 million in Q2 2025. Basic EPS moved between a loss of US$0.17 per share and a profit of...

In April 2026, Taylor Morrison Home reported that first-quarter 2026 revenue fell to US$1,387.09 million and net income to US$98.63 million, while also completing a buyback of 10,131,873 shares for US$619.97 million under its October 2024 authorization. The combination of weaker quarterly earnings and the completion of a sizeable repurchase program highlights how the company is balancing softer operating results with active capital returns. We’ll now examine how the sharp year-over-year drop...

In late April 2026, APi Group reported first-quarter 2026 sales of US$1,982 million and net income of US$57 million, raised its full-year 2026 net revenue outlook to between US$8.48 billion and US$8.68 billion, issued second-quarter revenue guidance, and filed an omnibus shelf registration for common stock, preferred stock, and debt securities. This combination of stronger recent results, higher full-year revenue targets, and expanded financing flexibility offers fresh insight into how APi...

Cboe Global Markets recently reported past first-quarter 2026 results showing revenue of US$1,272.8 million and net income of US$385.7 million, with earnings per share rising sharply year over year. Alongside record revenue and profits, the company announced a workforce reduction of 20% and plans to exit or sell Cboe Canada and Cboe Australia to concentrate on higher-growth derivatives and data businesses. We’ll now examine how Cboe’s record earnings and major realignment toward core...

Vornado Realty Trust (VNO) opened 2026 with Q1 funds from operations of US$106.3 million, or US$0.56 FFO per share, with the stock trading around US$30.26. Over the last few quarters, the company has reported quarterly revenue between US$448.4 million and US$487.8 million, while basic EPS moved between US$0.003 and US$3.87. This performance came alongside trailing 12 month net income of US$842.9 million and a net margin of 45.2%, supported by a large one off gain of US$925.2 million. For...

Blue Bird (NasdaqGM:BLBD) has appointed Steve Girardin to its board of directors. The appointment follows Blue Bird’s acquisition of full ownership of the Micro Bird joint venture. The move consolidates Blue Bird’s position in the school bus market and updates its board agreement and related party disclosures. For investors tracking the school transportation sector, Blue Bird is a focused player in the design and manufacturing of school buses, with an emphasis on North America. Bringing...

If you are wondering whether Bitmine Immersion Technologies at US$23.10 is still offering value or if the best opportunity has already passed, this breakdown will help you frame the stock in valuation terms instead of just headlines. The stock has been volatile, with a 7.5% return over the last week, 18.8% over the last month, a 25.9% decline year to date, and a 175.1% return over the last year. Recent market interest in Bitmine Immersion Technologies has been shaped by ongoing attention to...

Dorman Products (DORM) opened 2026 earnings season with Q1 numbers set against a recent run of steady results, including Q4 2025 revenue of US$537.9 million and basic EPS of US$0.38 on net income of US$11.6 million. Over the last six reported quarters, revenue has ranged between US$503.8 million and US$543.7 million while quarterly basic EPS has moved from US$1.77 to US$2.50, framing a business that has been consistently profitable. With a trailing 12 month net profit margin of 9.6% and...

In late April 2026, partner GSK announced that the FDA accepted for Priority Review the New Drug Application for bepirovirsen, an antisense therapy for chronic hepatitis B licensed from Ionis, while Ionis also raised its 2026 total revenue guidance to US$875 million–US$900 million and reported first-quarter revenue of US$246.09 million with a reduced net loss of US$92.53 million. Together, the expedited regulatory path for bepirovirsen and Ionis’ higher full-year revenue outlook highlight...

In April 2026, Cypress Grove, Make Time Wellness and Pure Genius Protein each announced new distribution deals with Target, bringing premium goat cheeses, women’s wellness supplements and functional protein beverages into hundreds of Target stores and onto Target.com across major U.S. markets. These partnerships deepen Target’s role as a one-stop destination for specialty food and wellness products, enriching its assortment in higher-margin, trend-focused categories that can support its...

Event context and recent stock performance Amneal Pharmaceuticals (AMRX) has drawn investor attention after recent share price moves, with the stock showing gains over the past week and month alongside a negative return over the past 3 months. For context, Amneal’s 1-day return is about 2.3%, with roughly 5.3% over the past week and 7.5% over the past month, compared with a 7.1% decline over the past 3 months and a 5.9% gain year to date. See our latest analysis for Amneal...

This article examines whether Merck, at around US$113 per share, still offers value or if most of the upside is already reflected in the price, by breaking down what the current valuation signals may be indicating. The stock has returned 2.8% over the last 7 days, is down 6.4% over the past 30 days, is up 6.3% year to date, and has delivered 48.4% over the past year. These moves may have influenced how the market views its risk and reward profile. Recent coverage has focused on Merck as a...

If you are wondering whether DHT Holdings at around US$19.10 is still good value or already pricing in a lot of optimism, the starting point is to look closely at what the market is paying for its fundamentals. The stock has recently posted returns of 4.4% over 7 days, 2.4% over 30 days, 62.7% year to date and 83.0% over the last year. This naturally raises questions about how much of the story is already reflected in the price. Recent news coverage has focused on DHT Holdings in the context...